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Abstract
Importance
Vasomotor symptoms (hot flushes and night sweats) and other symptoms, including
depression, anxiety and panic attacks, are commonly experienced by menopausal women
and have been associated with an unfavourable cardiovascular risk profile.
Objective
To investigate whether presence of menopausal symptoms is associated with the develop-
ment of cardiovascular disease (CVD).
Methods
Five electronic databases (Medline, EMBASE andWeb of Science) were search until Feb-
ruary 17th, 2015 to identify relevant studies. Observational cohort studies or randomised
intervention studies were eligible for inclusion if they followed participants prospectively (at
least 1 year of follow-up), and reported relevant estimates on the association of any vaso-
motor symptoms, or other menopausal symptoms, with risk of CVD, coronary heart disease
(CHD), or stroke in perimenopausal, menopausal, or postmenopausal women. Data were
extracted by two independent reviewers using a pre-designed data collection form. Sepa-
rate pooled relative risks (RRs) for age and non-established cardiovascular risk factors
(e.g., education, ethnicity) adjusted data and for established cardiovascular risk factors and
potential mediators-adjusted data (e.g., smoking, body mass index, and hypertension) were
calculated.
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Results
Out of 9,987 initially identified references, ten studies were selected, including 213,976
women with a total of 10,037 cardiovascular disease outcomes. The age and non-estab-
lished cardiovascular risk factors adjusted RRs) [95% confidence intervals] for development
of CHD, Stroke and CVD comparing women with and without any menopausal symptoms
were 1.34 [1.13–1.58], 1.30 [0.99–1.70], 1.48 [1.21–1.80] respectively, and the correspond-
ing RRs adjusted for cardiovascular risk factors and potential mediators were 1.18 [1.03–
1.35], 1.08 [0.89–1.32], 1.29 [0.98–1.71]. However, these analyses were limited by potential
unmeasured confounding and the small number of studies on this topic.
Conclusion
Presence of vasomotor symptoms and other menopausal symptoms are generally associ-
ated with an increased risk of cardiovascular disease, which is mainly explained by cardio-
vascular risk factors.
Introduction
Hot flushes (also known as hot flashes) along with night sweats are collectively known as vaso-
motor symptoms (VMS). These well-known symptoms of the menopause are commonly expe-
rienced by menopausal women[1]. 50.3%[2] to 82.1%[3] of menopausal women experience
VMS, and the intensity and duration of these symptoms also vary[3]. In addition to VMS,
menopausal women often experience a range of other symptoms including anxiety, depression,
irritability, fatigue, decreased libido, insomnia, and panic attacks, among others[4–7].
Menopausal transition represents a critical period in women’s lives that marks an increase
in cardiovascular disease (CVD) risk. Traditional CVD risk factors, such as reduced glucose
tolerance, increased blood pressure and endothelial dysfunction [8, 9], tend to become very
present during menopausal transition and post-menopausal years which can partly explain the
augmentation in CVD risk among women. The natural decline in oestrogen levels during men-
opause has been associated with the increase in CVD risk among post-menopausal women
[10]. Similarly, VMS are postulated to originate from changes in brain neurotransmitters and
instability in the hypothalamic thermoregulatory center brought about by decline in oestrogen
levels [11].
Oestrogen supplementation therefore has been considered as the most effective treatment
for these symptoms [12]. However, it remains unclear whether presence of menopausal symp-
toms is associated with the development of CVD[13]. Since menopausal symptoms can vary
greatly between women, they might help identify women at greater CVD risk that could benefit
from effective preventative strategies.
In the present study, we aimed to synthesise all available observational evidence of cardio-
vascular disease risk in relation to either VMS or non-vasomotor symptoms of menopause,
including depression, insomnia, and panic attacks, to determine the association between VMS
and non-vasomotor symptoms of menopause with risk of cardiovascular disease.
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Methods
Data Sources, Search Strategy and Eligibility Criteria
This review was conducted in accordance with the PRISMA[14] and MOOSE[15] guidelines
(S1 and S2 Appendices). Two independent authors (TM and COW), in duplication, sought
studies published before February 17, 2015 (date last searched) using Medline, EMBASE and
Web of Science databases. The computer-based searches combined terms related to the expo-
sure (eg, hot flashes, night sweats) and outcomes (eg, cardiovascular disease, coronary disease),
without any language restriction. Details on the search strategy are provided in S3 Appendix.
Studies were sought that had reported on associations of vasomotor symptoms (defined as hot
flashes and/or night sweats), or menopausal symptoms such as depression, insomnia, or panic
attacks, with vascular outcomes defined as composite CVD (combination of CHD and stroke),
fatal or non-fatal coronary heart disease (CHD), or stroke. CHD events included myocardial
infarction, coronary artery bypass graft, ischemic heart disease or sudden cardiac death if
caused by myocardial infarction and CHD deaths. Stroke included both haemorrhagic and
ischemic cerebrovascular events.
Study Selection
Observational cohort studies or randomised intervention studies were eligible for inclusion if
they followed participants prospectively (at least 1 year of follow-up), and reported relevant
estimates on the association of any vasomotor symptoms, or other menopausal symptoms
(defined above), with risk of composite CVD, fatal or non-fatal CHD, or stroke in perimen-
opausal, menopausal, or postmenopausal women. Two independent reviewers, working in
pairs, screened the titles and abstracts of all initially identified studies according to the selection
criteria. In case of disagreement, decision was reached through consensus or consultation with
a third independent author (RC and SC). Full texts were retrieved from studies that satisfied all
selection criteria.
Data Extraction
Data were extracted by two independent authors (COW and SK). A predesigned data extrac-
tion form was used to collect relevant information. This included questions on study size;
study design; baseline population; location; age at baseline; duration of follow-up; reported
degree of adjustment (defined as ‘+’ when RRs were adjusted for age and non-established car-
diovascular risk factors (e.g., education, income, ethnicity) and “++”further adjustment for
established vascular risk factors and potential mediators (e.g., body mass index, smoking status,
lipids, hypertension); type and numbers of vascular outcomes and reported RRs. Additionally,
in the case of multiple publications, the most up-to-date or comprehensive information was
included.
Assessing the Risk of Bias
Bias within each individual study was evaluated by two independent reviewers (TM and COW)
using the validated Newcastle-Ottawa Scale, a semi-quantitative scale designed to evaluate the
quality of nonrandomized studies[16]. Study quality was judged on the selection criteria of par-
ticipants, comparability of cases and controls, and exposure and outcome assessment. Studies
that received a score of nine stars were judged to be of at low risk of bias; studies that scored
seven or eight stars were considered at medium risk; those that scored six or less were consid-
ered at high risk of bias.
Menopausal Symptoms and Cardiovascular Disease
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Data Synthesis and Analysis
The inverse variance weighted method was used to combine relative risks to produce a pooled
relative risk using random- effects meta-analysis models to allow for between study heteroge-
neity. Separate summary estimates were obtained for age and potential cardiovascular risk fac-
tors adjusted data (e.g., education, income, ethnicity) and for established risk factors and
potential mediators-adjusted data (e.g., body mass index, smoking status, lipids, hypertension).
Heterogeneity was assessed using the Cochrane χ2 statistic and the I2 statistic. Publication bias
was evaluated through a funnel plot and Egger’s test. All tests were two-tailed and p-values of
0.05 or less were considered significant. STATA release 13 (Stata Corp, College Station, Texas)
was used for all statistical analyses.
Results
The search strategy identified 9,954 unique citations. Following initial screening based on titles
and abstracts, 54 articles were retrieved and evaluated further. Of these articles, 48 were
excluded for reasons shown in Fig 1 and S4 Appendix. The remaining 12 articles[17–28]
(based on 10 distinct studies) were included in the review and meta-analysis (Table 1). Conse-
quently, 213,976 individuals were included within the meta-analysis, with a total of 10,037
CVD outcomes. The average follow-up ranged from 5.3 to 15 years (Table 1). Eight studies
included women from the USA, whilst the remaining study included Dutch, Swedish and Fin-
ish participants. The age of participants ranged from 30 to 89 years. Three studies assessed
VMS whereas the rest of the included studies assessed other menopause symptoms; 4 studies
assessed depression, 2 sleep disturbance and insomnia, and 1 study panic attacks (S1 Table).
All available studies were prospective cohorts in design which were judged as medium or high-
quality studies, with few potential source of bias coming from participant selection (Table 2).
Association of Menopausal Symptoms and CHD
Menopausal symptoms, either VMS or other symptoms, in relation to risk of developing CHD
were reported in ten prospective observational studies, three of which assessed VMS and seven
assessed other menopausal symptoms. Pooled RRs for subsequent development of CHD,
adjusted for age along with other potential cardiovascular risk factors, were 1.34 (95%CI: 1.13–
1.58) when comparing women with and without VMS (70,814 participants, 1,860 events), and
1.48 (95% CI: 1.20–1.83) when comparing women with and without non-VMS (190,503 partic-
ipants, 6,789 events) (Fig 2). Whilst the pooled RR, adjusted for age and other potential cardio-
vascular risk factors, comparing women with and without any menopausal symptoms, using
data from 261,317 women with 8,649 CHD outcomes, was 1.34 (95%CI: 1.13–1.58) (Fig 2).
Further adjustment for established cardiovascular risk factors and potential mediators attenu-
ated but did not abolish the associations of VMS (RR = 1.28; 95%CI = 1.08; 1.52) and of any
menopausal symptoms (RR = 1.18; 95%CI = 1.03; 1.35) with CHD. In contrast, there was no
significant association between non-VMS and the risk of CHD after adjustment for established
cardiovascular risk factors and potential mediators (RR = 1.14; 95%CI = 0.98; 1.34) (Fig 2).
There was evidence of between-study heterogeneity for non-VMS and any for menopausal
symptom analyses (I2 = 92% (95%CI: 86%, 96%) and χ2: p<0.001 for non-vasomotor symp-
toms and I2 = 91% (95%CI:85%, 95%) and χ2: p<0.001 for all menopausal symptoms). There
was no evidence of heterogeneity for the VMS analysis (I2 = 35% and χ2: p = 0.21 for VMS)
(Fig 2). Restricting the CHD outcome to fatal CHD events only, no associations were found
between any menopausal symptoms, VMS or non-VMS, with fatal CHD in both models
(S1 Fig).
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Association of Menopausal Symptoms and Stroke
Menopausal symptoms in relation to subsequent stroke risk were reported in three prospective
observational studies; VMS was evaluated by one study and two studies assessed non-VMS.
From the single study evaluating stroke risk in women with and without VMS, the age and
potential risk factors- adjusted RR was 1.43 (95% CI: 1.07–1.92) (60,027 participants, 1226
stroke events) (Fig 3). Age and potential cardiovascular risk factors- adjusted summary esti-
mate of the RR was 1.34 (95%CI: 0.73–2.46) when comparing women with and without non-
VMS (97,045 participants, 504 stroke events) (Fig 3). The pooled RR for subsequent stroke,
adjusted for age and potential cardiovascular risk factors, was 1.30 (95% CI: 0.99–1.70) when
comparing the presence and absence of any menopausal symptoms (157,072 participants,
1,727 stroke events) (Fig 3). After multiple adjustments for cardiovascular risk factors and
potential mediators, the overall summery estimates of the RRs decreased to 1.14 ((95% CI:
Fig 1. Flow diagram of studies included in the current review.
doi:10.1371/journal.pone.0157417.g001
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Table 1. General characteristics of prospective studies of cardiovascular disease outcomes included in review.
Lead Author,
Publication
Date
Name of
study
Location Baseline
survey
Baseline
age
range, yr
Population
source
Average
follow up,
yr
No of total
participants
No. of
cases
Outcome Covariates adjusted for
Ahto, 2007[24] - Finland 1991–
1991
64 Population
register
12c 378 21 CHD
mortality
Age, marital status, social
status, number of
medicines.
Penninx, 1998
[23]; Mendes
de Leon, 1998
[28]
EPESE USA 1988 65 Healthcare
register.
4a 2812 557 Incident
CVD, CHD
and CHD
mortality
Age, sex, smoking, alcohol
intake, body mass index,
blood pressure, history of
stroke, diabetes, cancer and
physical disability.
Chandola, 2010
[27]
WHII USA 1985–
1988
35–55 Healthcare
register
15 3234 450 Incident
CHD
No adjustment
Ferketich, 2000
[25]
NHANES I USA 1982–
1984
30 Healthcare
register
8.3 5006 187 Non-fatal
CHD and
CHD
mortality
Age, poverty index,
smoking, hypertension,
diabetes and body mass
index.
Gast, 2011[17] EPOS/
WHILA
Netherlands
& Sweden
1995–
2000
46–64 Screening
program
10.3 10,787 606 Incident
CHD
Age, education, smoking,
physical activity,
ovariectomy, hormone
therapy use, oral
contraceptive use,
menopausal state, BMI,
SBP, DBP, total cholesterol
Sands-Lincoln,
2013[18]
WHI USA 1993–
1998
50–79 Healthcare
register
10.3 86,329 7,257 CVD and
incident
CHD
Age, race, education,
income, smoking, BMI,
physical activity, alcohol
intake, depression,
diabetes, high BP,
hyperlipidemia, comorbid
conditions
Smoller, 2007
[19]
MIMS USA 1997–
2000
51–83 Healthcare
register
5.3 3,369 81 Incident
CHD and
Stroke.
Age, race, income, BMI,
alcohol, hormone use, high
cholesterol requiring
medication, history of DM
treatment, smoking,
depression, history of AF,
hypertension status,
moderate to strenuous
activity for longer than 20
minutes 3 or more times a
week, history of MI, CABG,
PTCA, stroke before
questionnaire administration
Svartberg,
2009[21]
Rancho
Bernado
USA 1984–
1987
50–89 Population
register
11.5 867 194 CHD
mortality
Past or current estrogen
and/or progestin use, BMI,
exercise, smoking
Whooley, 1998
[26]
SOF USA 1988–
1990
67 Healthcare
register
6 7518 127 CHD
mortality
Age, history of myocardial
infarction, stroke, chronic
obstructive pulmonary
disease, hypertension,
diabetes, smoking,
perceived health and
cognitive function.
W-Smoller,
2004[20];
Szmuilowicz
2011[22]
WHI-OS USA 1994–
1998
50–79 Healthcare
register
9.7 93,676 2,557 CVD,
incident
CHD and
Stroke.
Age, race, education,
income, BMI, cholesterol,
smoking, hormone therapy,
physical activity, and
hypertension status
(Continued)
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0.82–1.59), 1.19 (95% CI: 0.68–2.11) and 1.08 (95% CI: 0.89–1.32) for VMS, non-VMS and any
menopausal symptoms respectively (Fig 3). There were some evidence of between study het-
erogeneity, however, in either meta-analysis: I2 = 51% and χ2: p = 0.15 for non-vasomotor
symptoms and I2 = 39% and χ2: p = 0.20 for all menopausal symptoms.
Association of Menopausal Symptoms and CVD
Four cohort studies reported menopausal symptoms in relation to subsequent risk of combined
CVD outcomes. All of these studies included American participants. Only one study examined
the association between VMS and the risk of CVD and showed a RR adjusted for age and
potential risk factors of 1.54 (1.27–1.86) (60,027 participants, 2,812 CVD events) for women
experiencing VMS compared to women who did not (Fig 4). Pooled RRs for subsequent devel-
opment of CVD, adjusted for age along with other potential established cardiovascular risk fac-
tors was 1.51 (95% CI: 1.12–2.02) (92,147 participants, CVD 7,758 events) when comparing
women with and without non-VMS (Fig 4). The pooled RR for CVD, adjusted for age but not
for conventional cardiovascular risk factors, comparing women with and without any meno-
pausal symptoms was 1.48 (95%CI: 1.21–1.80) (152,174 participants with 10,570 CVD events,
Fig 4). Multiple adjustment for established cardiovascular risk factors attenuated the overall
RRs: 1.23 (95% CI: 1.00–1.52) for VMS, 1.40 (95% CI: 0.88–2.25) for non-VMS and 1.29 (95%
CI: 0.98–1.71) for any menopausal symptom (Fig 4). There was evidence of between-study
Table 1. (Continued)
Lead Author,
Publication
Date
Name of
study
Location Baseline
survey
Baseline
age
range, yr
Population
source
Average
follow up,
yr
No of total
participants
No. of
cases
Outcome Covariates adjusted for
Total 213,976 12,037
a median
c total follow-up AF, atrial ﬁbrillation; BMI, body mass index; CABG, coronary bypass graft surgery; CHD, coronary heart disease; CVD, cardiovascular
disease; DM, diabetes mellitus; DBP, diastolic blood pressure; EPESE, Established Populations for Epidemiological Studies of the Elderly; EPOS,
Eindhoven Perimenopausal Osteoporosis Study; MI, myocardial infarction; MIMS, Myocardial Ischemia and Migraine Study; PTCA, percutaneous
transluminal coronary angioplasty; BP, systolic blood pressure; SOF, Study of Osteoporotic Fractures; WHILA, Women’s Health in the Lund Area;
WHI-OS, Women’s Health Initiative Observational Study.
doi:10.1371/journal.pone.0157417.t001
Table 2. Assessment of study quality through the Newcastle-Ottawa Scale.
Lead Author, Publication Date Selection Comparability Outcome
W-Smoller, 2004; Szmuilowicz 2011 ** ** ***
Smoller, 2007 ** ** **
Svartberg, 2009 ** * ***
Gast, 2011 *** ** ***
Sands-Lincoln, 2013 *** ** ***
Penninx, 1998, Mendes de Leon, 1998 *** ** **
Ahto, 2007 ** * ***
Ferketich, 2000 ** ** ***
Whooley, 1998 ** * ***
Chandola 2010 ** ***
Stars are awarded such that the highest quality studies with low risk of bias are awarded up to nine stars
doi:10.1371/journal.pone.0157417.t002
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Fig 2. Relative risks of coronary heart disease associated with menopausal symptoms. Basic model: adjusted for age and non-established
cardiovascular risk factors; Fully-adjusted model, adjusted for established cardiovascular risk factors and potential mediators. VMS, vasomotor symptoms;
vasomotor symptoms include hot flashes and /or night sweats; All, includes vasomotor and other menopausal symptoms; Other, includes menopausal
symptoms such as depression, insomnia, and panic attacks. Assessment of heterogeneity for basic model: All symptoms, X2 7 = 81.22, I2 = 91%, 85 to
95%; P < 0.001; vasomotor symptoms, X2 1 = 1.55, I2 = 35%; P = 0.213; other symptoms, X2 5 = 63.48, I2 = 92%, 86 to 96%; P < 0.001. Assessment of
heterogeneity for fully-adjusted model: All symptoms, X2 6 = 29.20, I2 = 79%, 58 to 90%; P < 0.001; vasomotor symptoms, X2 1 = 0.09, I2 = 0%; P = 0.762;
other symptoms, X2 4 = 22.63, I2 = 82%, 59 to 92%; P < 0.001.
doi:10.1371/journal.pone.0157417.g002
Fig 3. Relative risks of stroke associated with menopausal symptoms. Basic model: adjusted for age and non-established cardiovascular risk factors;
Fully-adjusted model, adjusted for established cardiovascular risk factors and potential mediators. VMS, vasomotor symptoms; vasomotor symptoms
include hot flashes and /or night sweats; All, includes vasomotor and other menopausal symptoms; Other, includes menopausal symptoms such as
depression, insomnia, and panic attacks. Assessment of heterogeneity for basic model: All symptoms, X2 2 = 3.26, I
2 = 39%, 0 to 81%; P = 0.196; other
symptoms, X2 1 = 2.03, I
2 = 51%, 0 to 87%; P = 0.154. Assessment of heterogeneity for full-adjusted model: All symptoms, X2 2 = 1.86, I
2 = 0%, 0 to 90%;
P = 0.395; other symptoms, X2 1 = 1.72, I
2 = 42%; P = 0.189.
doi:10.1371/journal.pone.0157417.g003
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heterogeneity in these meta-analysis: I2 = 72% (95%CI: 4%, 92%) and χ2: p = 0.045 for non-
VMS; I2 = 7% (95%CI: 12%, 92%) and I2 = 70% (95%CI: 13%, 90%) and χ2: p = 0.02 for all
menopausal symptoms combined.
Publication Bias
Under visual examination, Begg’s funnel plots for studies assessing the risk of CHD (S2 Fig) or
combined cardiovascular outcomes (S2 Fig) were not symmetrical, and therefore, providing
evidence for publication bias. This was further supported by the results of Egger’s test which
were significant for both CHD and composite CVD, in particular for the established cardiovas-
cular risk factors and potential mediators-adjusted data (S2 Fig). No evidence of publication
bias was observed for fatal CHD analysis, either graphically from the funnel plot (S2 Fig) or
quantitatively (P = 0.60 for Egger’s test asymmetry).
Discussion
This is the first meta-analysis investigating the association between the presence of menopausal
symptoms and subsequent development of cardiovascular disease. Overall we found that VMS
and other menopausal symptoms are associated with increased risk of CHD, stroke or CVD.
While the associations observed for menopausal symptoms with stroke and overall CVD could
be explained, at least in part, by established cardiovascular risk factors; the association between
menopausal symptoms and CHD was only partially attenuated, however, remained significant
once corrected for cardiovascular risk factors and potential mediators.
Our study showed that VMS are associated with an increased risk of CVD, which was atten-
uated after adjustment for cardiovascular risk factors. These results are in line with the notion
Fig 4. Relative risks of cardiovascular disease associated with menopausal symptoms. Basic model: adjusted for age and non-established
cardiovascular risk factors; Fully-adjusted model, adjusted for established cardiovascular risk factors and potential mediators. VMS, vasomotor symptoms;
vasomotor symptoms include hot flashes and /or night sweats; All, includes vasomotor and other menopausal symptoms; Other, includes menopausal
symptoms such as depression, insomnia, and panic attacks. Assessment of heterogeneity for basic model: All symptoms, X2 3 = 9.95, I2 = 70%, 13 to 90%;
P = 0.019; other symptoms, X2 2 = 7.05, I2 = 72%, 4 to 92%; P = 0.045. Assessment of heterogeneity for full-adjusted model: All symptoms, X2 3 = 8.68,
I2 = 65%, 0 to 88%; P = 0.034; other symptoms, X2 2 = 8.67, I2 = 77%, 25 to 93%; P = 0.013.
doi:10.1371/journal.pone.0157417.g004
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that menopausal symptoms may reflect an increased risk of CVD[13]. As well as other meno-
pausal symptoms, VMS might serve as a CVD risk marker, as women with VMS may have a
higher prevalence of other CVD risk factors [9, 13, 29, 30], with conventional CVD risk factors
(e.g., hypertension and total cholesterol) being possible mediators in the association between
VMS and CVD. Although epidemiological studies such as those included in this review cannot
provide causal evidence, some previous findings indicate that menopausal women with VMS
have a higher prevalence of CVD risk factors including higher blood pressure and cholesterol
levels [9, 29].
On the other hand, mental health disorders, including depression, anxiety and panic attacks
are already known to be CVD risk factors in both men and women of any age [31–33]. Short
and long sleep duration, indicative of poor physical and mental health, has also been associated
with CVD in the general population [34]. These different risk factors may work in tandem, as
for instance depression has been implicated in the association between sleep quality and CVD
[35]. It has also been suggested that these symptoms affect CVD risk through established risk
factors such as raised BMI [36, 37]. Moreover, depression and anxiety may result in autonomic
activation, leading to increased blood pressure and heart rate and decreased endothelial func-
tion [38, 39] or through affecting coagulation, by increasing platelet activity and plasma viscos-
ity among others [38]. The sympathetic nervous activation following the panic attacks could
also mediate an increased CVD risk [40].
Any results regarding the association between menopausal symptoms and CVD should be
cautiously interpreted, as women with symptoms are more likely to commence hormone ther-
apy than women without symptoms. Hormone therapy is taken to ameliorate menopausal
symptoms, but might adversely affect the development of CVD [8]. Although several of the
included studies adjusted the associations for hormone therapy use, the possibility of residual
confounding cannot be entirely eliminated. However, the most common reason for using hor-
mone therapy is VMS [41]; therefore if there was residual confounding by hormone therapy
use, an association with VMS over and above other menopausal symptoms would be expected.
Our results might indicate the potential usefulness of menopausal symptoms in assessing
CVD risk among women. As up to 20% of CHD events in women occur in the absence of con-
ventional risk factors [42], better risk assessment among women is warranted. The magnitude
of the observed association between menopausal symptoms and CVD (RR of 1.54) is similar to
the estimates reported for other female-specific CVD risk factors such as gestational diabetes
[43] and pregnancy-induced hypertension[44], which have recently been implicated for CVD
risk classification among women by the American Heart Association[45]. Considering this
potential, subsequent studies to further evaluate these associations are warranted.
This review underscores a number of gaps in the literature concerning CVD risk and meno-
pausal symptoms. For instance (i) not all available studies assessed the severity or duration of
menopausal symptoms, (ii) and interaction with the age and/or stages of menopause at which
women experienced these symptoms was not consistently evaluated. Recent evidence shows
that the predictive value of VMS for clinical CVD events may vary with onset of VMS at differ-
ent stages of menopause; e.g. Szmuilowicz et al. found that early VSM were not associated with
increased CVD risk, while late VMS were associated with increased CHD risk and all-cause
mortality[46]. Also, VMS were often grouped together, impeding the assessment of individual
symptoms. Experiencing menopausal symptoms in isolation or in combination might carry
different cardiovascular risk[17],[21].
This review involved aggregate data from 213,613 women from the general population with
over 10,000 cardiovascular events. A number of limitations, however, need to be considered. A
number of studies did not adjust for several CVD risk factors; including alcohol consumption
[17, 20–22] and socioeconomic status[17, 19–23]. Moreover, the results might also be subject
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to residual confounding. Due to using self-reported exposure and not specifying whether
women with CVD at baseline were excluded, most studies failed to score well on selection as
indicated by the Newcastle-Ottawa Scale. Although there is a risk of reverse-causation, one
study excluded events that occurred in the first 6 months of follow-up, which had no material
effect on the association[20]. Between-study heterogeneity was found in a number of analyses,
which may have resulted from different levels of adjustment and differing methods of case
ascertainment (ranging from death certificates to self-report validated by record linkage). Also,
another potential source of bias include possible misclassification of exposure. The age-range
of women included in our analysis varies across the included studies, with three studies includ-
ing women age 64 and above, and therefore the symptoms can occur beyond the menopausal
transition. However, two of these studies examined the association of menopausal symptoms
with CHD-mortality, and therefore, may have had little or no impact on the other results
reported in this systematic review. Furthermore, VMS and other menopausal symptoms were
assessed by questionnaire which is subject to some measurement error. However, because the
outcome in all studies included in this systematic review was assessed prospectively, the subjec-
tive measure of menopausal symptoms would likely lead to non-differential misclassification
with respect to the outcome, and therefore would likely bias our estimates toward the null in
our analysis. Also, a major limitation of the studies included in our systematic review is the reli-
ance on retrospective self-report of menopausal symptoms, particularly of VMS, which are
subject to fault memory and reporting bias. Assessing VMS physiologically with, for example,
an ambulatory hot flash monitor to measure skin conductance, would be an alternative objec-
tive measure of vasomotor symptoms. Also, the studies varied on the time when they assessed
the presence of menopausal symptoms, which may be an important factor in determining the
risk for CVD. Data from the Women’s Health Initiative suggest that the predictive value of
vasomotor symptoms for cardiovascular risk may vary with onset of vasomotor symptoms at
different stages of menopause[22]. Furthermore, studies usually combined assessment of VMS
frequency and severity, constructs which are not interchangeable. The majority of studies were
based in a single country (USA). Given that CVD rates, menopausal symptoms and age at
menopause[47] all vary between countries, it is possible that the strength or existence of the
associations also varies by population. Therefore, to improve the generalizability of the find-
ings, these associations would need to be evaluated in other populations. Finally, we found evi-
dence of reporting bias in our systematic review, and therefore, some relevant studies may have
been overlooked in the current systematic review.
Conclusion
The evidence from observational studies indicate that women who experience VMS and other
menopausal symptoms, including depression, anxiety and panic attacks during menopause are
at greater risk of developing CVD. Further studies are needed to reliably establish which meno-
pausal symptoms are independently associated with CVD outcomes and further clarify the
potential mechanisms behind these associations.
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